

## **Web material**

Web Table 1. Variable codes.

Web Table 2. Propensity score supplementary data.

Web Table 3. Repartition of patients according to their ADT duration before ABI / ENZ initiation.

Web Table 4. Survival rates at different time points.

Web Table 5. Baseline Characteristics of Chemotherapy-naïve mCPRC patients, France, July 2015 – June 2017.

Web Table 6. Duration of ABI and ENZ treatments.

Web Table 7. Subsequent therapy for prostate cancer.

Web Figure 1. Study schematic.

Web Figure 2. Temporal trend of initiation of new hormonal therapies.

Web Figure 3. Propensity score supplementary curves.

Web Figure 4. E-value estimation ([www.evalue-calculator.com](http://www.evalue-calculator.com))

**Web Table 1. Variable codes**

Variable label	Definition	ICD-10 codes fro hospitalisation or Long term diseases (LTD)	Medical act code	ATC code	Biology codage
<b>EXCLUSION CRITERIA</b>					
Other active cancer	other active cancer than Prostate cancer	C00.x-C97.x, D00.x-D09.x excluding C61.x, D075			
<b>EXPOSURE</b>					
ABI treatment	Abiraterone exposure			L02BX03	
ENZ treatment	Enzalutamide exposure			L02BB04	
CABAZI treatment	Cabazitaxel exposure			L01CD04	
<b>HISTORY OF DISEASES AND DRUGS EXPOSURE</b>					
Chemotherapy session	Chemotherapy exposure for prostate cancer (chemo session or hospitalisation for prostate cancer)	main diagnosis = Z51.1 and related diagnosis = C61 or main diagnosis = C61 and associated diagnosis = Z51.1			
ADT exposure	Exposure to ADT preceeding ABI or ENZ exposure		JHFA010	L02AE, L02BB, G03HA, L02BX02	
Curietherapy - brachytherapy	History of curietherapy - brachytherapy		JGNL001		

Prostatectomy	History of prostatectomy		JGFC001, JGFA006, JGFA011, JDFA019, JDFA020, JDFA021, JDFA022, JDFA023, JDFA024, JDFA025		
Radiotherapy	History of radiotherapy		ZZNL.x in patients with ICD-10 C61 and exclusion of all ICD-10 codes of cancer		
Diabetes (with or without organ damage)	History of diabetes	E100, E101, E106, E108, E109, E110, E111, E116, E118, E119, E120, E121, E126, E128, E129, E130, E131, E136, E138, E139, E140, E141, E146, E148, E149, E102-E105, E107, E112-E115, E117, E122-E125, E127, E132-E135, E137, E142-E145, E147	BGNA001, BGNP001, BGNP004, BGNP006, BGNP007, BGNP008	A10% <i>(at least 3 reimbursements)</i>	
Liver insufficiency	History of liver insufficiency	B18.x, K70.0-K70.3, K70.9, K71.3-K71.5, K71.7, K73.x, K74.x, K76.0, K76.2-K76.4, K76.8, K76.9, Z94.4, I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K72.9, K76.5-K76.7			
Non-drug induced liver injury	History of [liver disease <= 3 y before inclusion, pancreatitis <= 1 y bef inc, cancer <= 1 y bef incl, HIV <= 1 y bef incl, alcohol use disorders <= 3 y bef incl]				

liver disease	History of liver disease in the 3 year before inclusion	B15.0, B15.9, B16.0-16.2; B16.9, B17.0-B17.2, B17.8, B18.0-B18.2, B18.8-B18.9, B19.0, B19.9, B25.1, B94.2, K71.3-71.5, K71.7, K72.1, K73.0-K73.2, K73.8-K73.9, K74.0-K74.2, K74.4-K74.6, K75.0-K75.1, K75.3-K75.4, K75.8-K75.9, K76.0-K76.1, K76.3-K76.9, K77.0, K77.8, R16.0, R17, R740, R79.1, R82.2, R94.5, T86.4, D68.4, K71.1, K71.1, K712, K716, K718, K719, K710, K752, K759, K762, K767, Z944		J05AF08, J05AF10-J05AF11, J05AB04, J05AE11, J05AE12, J05AX14-16, J05AX65-67, L03AB05, L03AB09-10, L03AB11	
pancreatitis	History of pancreatitis in the 1 year before inclusion	K85.x			
cancer	History of cancer in the 1 year before inclusion	C00-C97, D00-D09, D37-D48, Z51.0, Z51.1			
HIV infection	History of HIV in the 1 year before inclusion	B20.x-B24.x, F02.4, R75.x, Z21.x		At least 2 reimbursements J05AE01-J05AE10, J05AF01-J05AF07, J05AF09, J05AG01, J05AG03-J05AG05, J05AR01-J05AR04, J05AR06, J05AR08-J05AR10, J05AR13, J05AX05, J05AX07-09, J05AX12	
alcohol use disorders	History of alcohol use disorders in the 3 year before inclusion	F10.x, K70.x, T51.x, E24.4, G31.2, G62.1, G72.1, I42.6, K29.2, K86.0, Z50.2, Z71.4, Z72.1,		At least 1 reimbursement N07BB	

Chronic Renal insufficiency (using Bannay et al definition*)	History of renal insufficiency	I12.0, I13.1, N03.2–N03.7, N05.2–N05.7, N18.x, N19.x, N25.0, Z49.0–Z49.2, Z94.0, Z99.2	JVJF004, JVJF008, JVJB001, JVJF003		
Hypertension	History of hypertension	See algorithm <sup>§</sup>			
Reimbursement of drugs licensed for hypertension or cardiac failure	Reimbursement of drugs licensed for hypertension or cardiac failure			C02A + C02B + C02CA06 + C02D + C02L + C03 + C07 <b>(exclusion of propranolol = C07AA05 + C08 + C09)</b>	
Ischemic heart diseases	History of MI, angina or other ischemic heart diseases	I20.x, I21.x, I22.x, I23.x, I24.x, I25.x			
Atherosclerosis and peripheral embolism	History of atherosclerosis and peripheral embolism	I70.x, I74.x			
Coronary revascularisation	History of coronary revascularisation		DDAF.x, DDPF002, DDMA.x, DDFF001, DDFF002		

Carotid and Peripheral angioplasty	History of angioplasty on carotid arteries and lower limbs		DHCA004 EBAA002 EBAF001 EBAF003 EBAF004 EBAF005 EBAF006 EBAF009 EBAF010 EBAF011, EBCA001 EBCA002 EBCA004 EBCA008 EBCA010 EBCA011 EBCA013 EBCA015 EBCA017 EBEA003 EBEA005 EBKA001, EBKA002 EBKA003, EBKA004 ECFA003 ECFA004 ECLF004 EDCA004 EDCA005 EEAA002 EEAFO01 EEAFO02 EEAF003, EEAFO04 EEAFO05 EEAF006 EECA001 EECA002 EECA003 EECA005 EECA006 EECA007 EECA008 EECA010 EECA012, EEGA001 EEGA002 EEKA001 EELF002, EGAF003 EGCA003 EGFA006 EJCA002 EJCA003 EJEA001 EMSA001 ENAF001, ENAF002 ENFA005 EPCA002 EZCA002 EZCA003 EZCA004 EZFA003 EZPA001		
Ischemic stroke	history of ishcemic stroke	I63.0-I63.5, G45.x			
Heart diseases (including cardiomyopathy)	history of hospitalisation for heart failure or LTD for heart failure	I099, I110, I130, I132, I42.x, I43.x, I50.x			
anticoagulant	History of anticoagulant reimbursement			At least 3 reimbursements B01AA, B01AE07, B01AF01, B01AF02	

antiplatelet inhibitors	History of antiplatelet inhibitors reimbursement			At least 3 reimbursements B01AC04, B01AC05, B01AC06, B01AC07, B01AC22, B01AC24, B01AC30, C10BX02 and specific drug "Aspegic (aspirin) 100mg nourrissons®" (CIP7: 3189363, CIP13: 3400931893639)	
Drugs affecting bone structure and mineralisation	History of drugs affecting bone structure and mineralisation reimbursement			At least 1 reimbursement M05BA04, M05BA07, M05BB03, M05BB04, G03XC01, H05AA02, Excluding [M05BA02, M05BA05]	
drug preventing the tumor bones complications	History of preventing the tumor bones complications reimbursement			At least 1 reimbursement M05BA03, M05BX04	
Opioids and derivates	history of opioids and derivates reimbursement			At least 2 reimbursements N02A	
Atrial fibrillation	History of atrial fibrillation	I48.x	DEQP003, DERP003, DERP004, DEPF001, DEPF006, DEPF012, DEPF014, DEPF025, DEPF033 and [(DAQM003 DEQP001, DEQP004, DEQP005, DKRP004, DZQJ001, DZQJ006, DZQJ008, DZQM002,		

			DZQM005, DZQM006, EQRP002, GLRP004) + oral anticoagulant reimbursement in the 60 days following the medical act]		
Dyslipidemia drugs	History of dyslipidemia drugs reimbursement			At least 1 reimbursement C10AA, C10AB, C10AX, C10B	
Smoking or chronic obstructive pneumopathy disorders	History of smoking or chronic obstructive pneumopathy disorders	F17.x, I731, J41.x-J44.x, T652, Z716, Z720		R03AC18, R03AC19, R03BB05, R03BB04, R03BB07, R03BB06, R03AL04, R03AL05, R03AK04, N07BA, N06AX12	
Obesity	History of overweight	E66.x	HFCA001, HFCC003, HFFA001, HFFA011, HFFC004, HFFC018, HFMA009, HFMA010, HFMC006, HFMC007, HGCA009, HGCC027, HFLE002, HFLC900, HFGC900, HFKC001, HFKA002, HFMC008, HFMA011, HFKA001		

Antiepileptic drugs or chronic / neuropathic pain drugs	History of antiepileptic drugs reimbursement			N03AA02, N03AA03, N03AB02, N03AB05, N03AD01, N03AD03, N03AE01, N03AF01, N03AF02, N03AF03, N03AF04, N03AG01, N03AG02, N03AG03, N03AG04, N03AG05, N03AG06, N03AX03, N03AX07, N03AX09, N03AX10, N03AX11, N03AX12, N03AX13, N03AX14, N03AX15, N03AX16, N03AX17, N03AX18, N03AX21, N03AX22, N05BA09	
PSA testing	PSA testing				7320, 7318, 7319
Charlson comorbidity index according to the Bannay et al definition*					
Myocardial infarction		I21.x			
Ischemic heart disease		I20.x, I21.x, I22.x, I23.x, I24.x, I25.x			
Congestive heart failure		I110, I130, I132, I50.x			

Peripheral vascular disease		I70.x, I71.x, I731.x, I738.x, I739.x, I771.x, I790.x, I792.x, K551.x, K558.x, K559.x Z958.x, Z959.x	EEAF.x, ECPF.x, ECFA.x, EBFA.x., EENF.x, EEPF.x, EEFA.x, EECA.x, ENNF.x, ENFA.x, DGAF.x, EDAF.x, DGFP.x, EDPF.x, DGFA.x, EDFA.x, DGCA.x, EDCA.x, EDPF.x, EDJF.x, EDKA.x, EDEA.x, EDLF.x, EDNF.x, EDPF.x, EDJF.x, EDMA.x, EANF002, ECNF002, ECJF001, ECCA007, ECCA009, ECCA003, ECCA002, ECMA001, ECKA002, EBNF001, EDEA001, EDLF007, EEJF001, EDCA005, ENAF001, ENAF002, DGKA004, EDNF003, EDKA002		
Cerebrovascular disease		G45.x, G46.x, H34.0, I60.x - I69.x			
Dementia		F00.x-F03.x, F05.1, G30.x, G31.1		N06D% <i>(at least 3 reimbursements)</i>	
Chronic pulmonary disease		I27.8, I27.9, J40.x-J47.x, J60.x-J67.x, J68.4, J70.1, J70.3		R03% except R03AA, R03AB, R03CA, R03CB <i>(at least 3 reimbursements)</i>	
Rheumatologic disease Connective tissue disease		M05.x, M06.x, M315, M32.x-M34.x, M351, M353, M360			
Peptic ulcer disease Ulcer disease		K25.x-K28.x			

Mild liver disease		B18.x, K70.0–K70.3, K70.9, K71.3–K71.5, K71.7, K73.x, K74.x, K76.0, K76.2–K76.4, K76.8, K76.9, Z94.4			
Moderate or severe liver disease		I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K72.9, K76.5–K76.7			
Diabetes Without complication		E100, E101, E106, E108, E109, E110, E111, E116, E118, E119, E120, E121, E126, E128, E129, E130, E131, E136, E138, E139, E140, E141, E146, E148, E149		A10% <i>(at least 3 reimbursements)</i>	
Diabetes with end-organ damage		E102–E105, E107, E112–E115, E117, E122–E125, E127, E132–E135, E137, E142–E145, E147	BGNA001, BGNP001, BGNP004, BGNP006, BGNP007, BGNP008		
Hemiplegia		G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0–G83.4, G83.9			
Moderate or severe renal disease		I12.0, I13.1, N03.2–N03.7, N05.2–N05.7, N18.x, N19.x, N25.0, Z49.0–Z49.2, Z94.0, Z99.2	JVJF004, JVJF008, JVJB001, JVJF003		
Any malignancy, including leukemia and lymphoma		C00.x–C26.x, C30.x–C34.x, C37.x–C41.x, C43.x, C45.x–C58.x, C60.x–C76.x, C81.x–C85.x, C88.x, C90.x–C97.x			
Metastatic solid tumor		C77.x–C80.x			
AIDS/HIV		B20.x–B22.x, B24.x, Z21.x			

\* Bannay et al. definition, see DOI: 10.1097/MLR.0000000000000471.

**\$ Hypertension algorithm:**

If in the previous year, ICD-10 code « I10 » in the main or related or associated diagnosis

OR

If in the previous year, ICD-10 code « I15 » in the main or related or associated diagnosis

OR

If patient has a « long term disease » with ICD-10 code « I10 »

OR

Reimbursement for HTA drugs (ATC classes C02A + C02B + C02CA06 + C02D + C02L + C03 + C07 (**exclusion** of propranolol = C07AA05 + C08 + C09) but patients **without** history of:

- ischemic stroke: ICD10 codes in main diagnosis "I63",
- and/or myocardial infarction: ICD10 codes in main diagnosis "I21",
- and/or coronaropathy diseases: ICD10 codes in main diagnosis "I20% / I21% / I22% / I23% / I24% / I25%",
- and/or congestive heart failure (thanks to French Quan\*\* algorithm) defined as, in main or related or associated diagnosis (but excluding ICD-10 code "I25", already in Coronaropathy disease algorithm) or long-term disease with the following ICD10 codes:

I099/I110/I130/I132/I420/I425/I426/I427/I428/I429/I43%/I50%/P290;

- and/or arterial thrombosis diseases: main diagnosis with ICD10 codes "I74" + and/or medical acts (CCAM) for thrombosis:  
('EEAF%' or 'ECPF%' or 'ECFA%' or 'EBFA%' or 'EENF%' or 'EEP%' or 'EEFA%' or 'EECA%' or 'ENN%' or 'ENFA%' or 'DGAF%' or 'EDAF%' or 'DGFP%' or 'EDPF%' or 'DGFA%' or 'EDFA%' or 'DGCA%' or 'EDCA%' or 'EDPF%' or 'EDJF%' or 'EDKA%' or 'EDEA%' or 'EDLF%' or 'EDNF%' or 'EDPF%' or 'EDJF%' or 'EDMA%' or cdc\_act

in ('EANF002', 'ECNF002', 'ECJF001', 'ECCA007', 'ECCA009', 'ECCA003', 'ECCA002', 'ECMA001', 'ECKA002', 'EBNF001', 'EDEA001', 'EDLF007', 'EEJF001', 'EDCA005', 'ENAF001', 'ENAF002', 'DGKA004', 'EDNF003', 'EDKA002').

\*\*Quan algorithm for congestive heart failure (ICD-10 codes): I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5–I42.9, I43.x, I50.x, P29.0.

**Web Table 2. Propensity score supplementary data.**Standardized differences before and after weighting

<b>Without Previous chemotherapy</b>	<b>Before Weighting</b>	<b>After Weighting</b>
Age	0.148	0.003
Duration of ADT T0 :		
<i>&lt; 2 years of ADT</i>	0.032	0.001
<i>Between 2 and 3 years of ADT</i>	0.008	0.002
<i>&gt; 3 years of ADT</i>	0.021	0.003
<i>No gap in the 6 previous months*</i>	0.017	0.002
Curative Radiotherapy	0.048	0.001
Diabetes	0.096	0.000
Moderate or severe renal disease	0.047	0.002
Hypertension	0.033	0.001
Atrial fibrillation	0.097	0.001
Ischemic heart diseases and/or Coronary revascularization	0.075	0.001
Recent use of anticoagulant	0.060	0.000
Recent use of antiplatelet inhibitors	0.071	0.001
Recent use of Drugs affecting bone structure and mineralization or preventing the tumor bones complications	0.086	0.002
Recent use of Opioids and derivates	0.016	0.000
Recent use of Dyslipidemia drugs	0.043	0.001
Obesity	0.087	0.000

\* Reimbursement in the last 6 months of the last 6 months before ABI or ENZ initiation

**Web Table 3. Repartition of patients according to their ADT duration before ABI / ENZ initiation**

	ABI		ENZ		Total	
	n	%	n	%	n	%
<b>&lt; 12 months</b>	1056	16.0	621	16.7	1677	16.3
<b>12-24 months</b>	1485	22.6	879	23.6	2364	22.9
<b>24-36 months</b>	1097	16.7	604	16.2	1701	16.5
<b>&gt; 36 months</b>	2781	42.2	1535	41.2	4316	41.9
<b>Unknown*</b>	166	2.5	84	2.3	250	2.4
<b>Total</b>	<b>6 585</b>	<b>100</b>	<b>3 723</b>	<b>100</b>	<b>10 308</b>	<b>100</b>

**Web Table 4. Survival rates at different time points.**

Follow-up	Abiraterone		Enzalutamide	
	Survival (%)	95% CI	Survival (%)	95% CI
3 Months	95.63	95.10, 96.09	97.28	96.69, 97.76
6 Months	91.43	90.73, 92.09	93.35	92.49, 94.12
9 Months	86.59	85.74, 87.40	88.68	87.60, 89.67
12 Months	81.45	80.48, 82.37	83.94	82.69, 85.09
15 Months	76.92	75.88, 77.92	78.78	77.39, 80.09
18 Months	71.31	70.18, 72.41	74.02	72.52, 75.45
21 Months	66.56	65.37, 67.73	68.50	66.87, 70.07
24 Months	61.50	60.25, 62.72	63.91	62.17, 65.60

**Web Table 5. Baseline Characteristics of Chemotherapy-naïve mCPRC patients, France, July 2015 – June 2017.**

	Source population		Weighted pseudo-population	
	ABI	ENZ	ABI	ENZ
n (%)	2530 (47.7)	2777(52.3)	47.7 %	52.3 %
Mean age in years (SD)	77.3 (8.6)	78.5 (8.8)	78 (8.7)	78 (8.7)
<b>Prostate cancer treatment and management<sup>s</sup></b>	<b>n (%)</b>	<b>n (%)</b>	<b>%</b>	<b>%</b>
<b>ADT exposure</b>				
ADT exposure with an ADT start date identified <sup>€</sup>	2098 (83)	2253 (81)	82.2	81.6
Median duration (IQR) of ADT (when ADT start date was identified), in months	24 (14-40.4)	24.4 (13.3 -40.7)	a	a
Brachytherapy	1 (0.04)	3 (0.1)	0.04	0.1
Prostatectomy	38 (1.5)	44 (1.6)	1.4	1.7
Radiotherapy <sup>€</sup>	234 (9.3)	247 (8.9)	9.5	8.7
Curative Radiotherapy	193 (7.6)	227 (8.2)	7.9	7.9
<b>PSA titration 1 year before inclusion</b>				
Median number (min-max) of PSA titrations	4 (3-5)	4 (3-5)	4 (3-5)	4 (3-5)
Mean number (SD) of PSA titrations	4.5 (1.9)	4.4 (2)	4.5 (1.9)	4.4 (1.9)
<b>Comorbidities*, n (%)</b>	<b>n (%)</b>	<b>n (%)</b>	<b>%</b>	<b>%</b>
Hypertension	1645 (65)	1813 (65.3)	65.2	65.2
Chronic renal insufficiency	94 (3.7)	125 (4.5)	4.1	4.1
Diabetes (with or without organ damage)	476 (18.8)	610 (22)	20.5	20.5
Atrial fibrillation	190 (7.5)	280 (10.1)	8.9	8.9
Heart disease (including cardiomyopathy)	72 (2.9)	108 (3.9)	3.2	3.4
Ischemic stroke	40 (1.6)	54 (1.9)	1.7	1.8
Atherosclerosis and peripheral embolism	49 (1.9)	82 (3)	2.2	2.6
Use of anticoagulants in the year before T0	304 (12)	372 (13.4)	12.9	12.8
Use of antiplatelet inhibitors in the year before T0	739 (29.2)	919 (33.1)	31.1	31.2
Use of dyslipidemia drugs in the year before T0	1024 (40.5)	1193 (43)	41.9	41.8
Ischemic heart disease and/or coronary revascularisation	320 (12.7)	420 (15.1)	13.9	13.9
Carotid and peripheral angioplasty	9 (0.4)	28 (1)	0.4	0.9
Smoking disorders or chronic obstructive pneumopathy	187 (7.4)	268 (9.7)	8.0	9.0
Alcohol use disorders	35 (1.4)	36 (1.3)	1.4	1.3
Obesity	113 (4.5)	180 (6.5)	5.5	5.5
Use of drugs affecting bone structure and mineralisation in the year before T0	51 (2)	64 (2.3)	1.9	2.5
Use of drug preventing tumor bone complications in the year before T0	311 (12.3)	268 (9.7)	11.2	10.6
Use of opioids and derivatives in the year before T0	496 (19.6)	523 (18.8)	19.2	19.2
<b>Modified CCI (according to Bannay et al.)<sup>&amp;</sup></b>	<b>n (%)</b>	<b>n (%)</b>	<b>%</b>	<b>%</b>
0	174 (6.9)	209 (7.5)	6.9	7.5
1	31 (1.2)	34 (1.2)	1.5	a1.1
2	1882 (74.4)	1979 (71.3)	72.7	72.8
≥ 3	443 (17.5)	555 (20)	19.0	18.5
<b>Component of the Modified CCI identified in the year before ABI / ENZ initiation</b>	<b>n (%)</b>	<b>n (%)</b>	<b>%</b>	<b>%</b>
Ischemic heart disease	275 (10.9)	359 (12.9)	12.0	12.0
Peripheral vascular disease	111 (4.4)	158 (5.7)	5.0	5.0
Cerebrovascular disease	95 (3.8)	124 (4.5)	4.1	4.1
Dementia	43 (1.7)	49 (1.8)	1.8	1.7
Chronic pulmonary disease	228 (9)	296 (10.7)	9.9	9.9
Rheumatic disease, connective tissue disease	17 (0.7)	23 (0.8)	0.7	0.8
Peptic ulcer disease, ulcer disease	4 (0.2)	5 (0.2)	0.2	0.2
Diabetes without complications	444 (17.6)	565 (20.4)	19.0	19.0
Diabetes with end-organ damage	14 (0.6)	23 (0.8)	0.7	0.7
Hemiplegia	9 (0.4)	16 (0.6)	0.4	0.6
Moderate or severe renal disease	67 (2.7)	74 (2.7)	2.9	2.4
AIDS/HIV	4 (0.2)	0 (0.0)	0.2	0.0

ABI: abiraterone; ADT: androgen deprivation therapy; ENZ: enzalutamide; IQR: interquartile range; mCPRC: metastatic castration-resistant prostate cancer.

<sup>s</sup> Prostate cancer treatment history used data from January 2009.

<sup>€</sup> Patients for whom an ADT start date was identified because sufficient history was available before ABI or ENZ start.

<sup>£</sup> Radiotherapy sessions, at least one session identified in the entire history (from January 2009).

\* Comorbidities were identified in the 3 years before T0 except if specifically mentioned.

& According to the Bannay et al. definition (DOI: 10.1097/MLR.0000000000000471), components of the modified Charlson comorbidity index were identified in the year before T0.

a The ADT duration was not considered as a continuous variable since patients could have more than 3 years of treatment (open category). The ADT duration was therefore considered in 3 categories (<1y; 1-2 y; >3y).

**Web Table 5. Duration of ABI and ENZ treatments.**

<b>Duration of treatment (in months)</b>	<b>ABI</b>		<b>ENZ</b>	
	Median	Q1, Q3	Median	Q1, Q3
Patients without discontinuation until death or Dec. 31 <sup>st</sup> , 2017	15.2	6.2, 27.0	20.4	14.0, 29.7
Patients who stopped treatment without switch*	8.8	3.8, 17.9	8.6	3.6, 14.8
Patients with treatment discontinuation and who switched**	10.8	6.0, 17.7	9.9	6.1, 15.5

ABI: abiraterone; ENZ: enzalutamide, Q3: Q1 stands for 1<sup>st</sup> quartile and Q3 for 3<sup>rd</sup> quartile.

\* No switch observed on the available follow-up.


\*\* Switch to ABI or ENZ or chemotherapy.

**Web Table 6. Subsequent therapy for prostate cancer.**

	ABI (n = 6 585)	ENZ (n = 3 723)
Patients with subsequent therapy, n (%)	3 542 (53.8%)	1313 (35.3 %)
Details of subsequent therapy, n (%*)		
	ABI .	676 (51.5 %)
	ENZ 2079 (58.7 %) .	
<i>1st line chemotherapy with docetaxel</i>	1422 (40.1%)	611 (46.5 %)
<i>1st line chemotherapy with CABA</i>	41 (1.2 %)	26 (2.0 %)

\* percent concern the number of patients with a specified therapy reported to the total number of patients with a subsequent therapy.

## Web Figure 1. Study schematic




\* First reimbursement date of ABI or ENZ in 2014-2017, proxy of progression to castration-resistant prostate cancer, \*\* and considered as the start of the follow-up (T0).


\$ Chronic renal failure, hypertension, diabetes, atrial fibrillation, cardiac failure, arterial ischemic disease.

€ Modified Charlson comorbidity index, antidiabetics, anticoagulants, platelet inhibitors, opiates, bisphosphonates, and bone metastasis treatment), and PSA titration.

**Web Figure 2. Temporal trend of initiation of new hormonal therapies**



### Web Figure 3. Propensity score supplementary curves



Web Figure 4. E-value estimation ([www.evalue-calculator.com](http://www.evalue-calculator.com))

